Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NCD Partnership

Eli Lilly HQ

Lilly and Sanford-Burnham reveal immunology collaboration

Will aim to discover and develop therapies in the field

- PMLiVE

AZ to screen 80,000 patients for genetic disease traits

Will work with Montreal Heart to investigate cardiovascular and diabetic signals

Eli Lilly HQ

Lilly and BioNTech partner on cancer immunotherapy

Lilly gets on board with the hottest research ticket in town

- PMLiVE

Transition takes on Lilly muscle-boosting drug

Lilly to receive just $1m upfront but could get up to $100m in milestones

- PMLiVE

Prescribing costs jump in England

New report finds that asthma and diabetes drugs the most costly to the NHS

Sanofi reception

Poor Lantus sales sees Sanofi’s diabetes unit fall

French firm hit by insulin pricing pressures and soon faces biosimilar threat

- PMLiVE

Takeda to pay $2.4bn to settle Actos cancer suits

Will be one of the largest drug safety settlements in US history

- PMLiVE

Relief as study finds no cardiovascular risk with Januvia

FDA continues to investigate safety of numerous diabetes therapies

- PMLiVE

Sanofi wins European approval for Lantus follow-up Toujeo

Long-acting insulin is a key part of the company's growth plans

- PMLiVE

Saxenda debuts in US with $1,000-a-month price tag

It is the first market for Novo Nordisk’s obesity therapy

Making a difference with mobile health

Sanofi talks to PME about its latest mHealth initiative and tackling the diabetes epidemic

- PMLiVE

AZ and Takeda drugs should carry heart failure warning

FDA panel claim diabetes drugs Onglyza and Nesina need label updates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links